Soleno Therapeutics (NASDAQ:SLNO) Downgraded to "Hold" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Soleno Therapeutics (NASDAQ:SLNO) from a "buy" to a "hold," reflecting mixed analyst views overall—MarketBeat data shows a consensus of Moderate Buy with a $104.54 price target while individual targets have been cut (e.g., TD Cowen to $85, Wells Fargo to $110).
• Soleno is facing material downside risks from multiple securities‑fraud class actions and investor alerts ahead of a May 5, 2026 lead‑plaintiff deadline, and Oppenheimer has trimmed expectations for the VYKAT XR launch and 2026 sales.
• The company beat quarterly estimates (EPS $0.80 vs. $0.64; revenue $91.7M vs. $88.6M) but the stock opened at $33.22—near its 52‑week low—with a high P/E (144.44) and weakening moving averages, signaling valuation and execution concerns despite the beat.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Sunday.

Several other research firms have also recently commented on SLNO. Wells Fargo & Company cut their price target on Soleno Therapeutics from $114.00 to $110.00 and set an "overweight" rating for the company in a research note on Friday, February 27th. Robert W. Baird set a $107.00 price objective on shares of Soleno Therapeutics in a research note on Tuesday, January 13th. TD Cowen cut their price objective on shares of Soleno Therapeutics from $120.00 to $85.00 and set a "buy" rating for the company in a research report on Thursday, February 26th. Weiss Ratings restated a "sell (d-)" rating on shares of Soleno Therapeutics in a research note on Thursday, January 22nd. Finally, Wolfe Research set a $60.00 target price on shares of Soleno Therapeutics in a report on Monday, January 12th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $104.54.

Soleno Therapeutics Stock Performance

NASDAQ SLNO opened at $33.22 on Friday. The firm has a market cap of $1.71 billion, a P/E ratio of 144.44 and a beta of -3.16. Soleno Therapeutics has a 52-week low of $32.15 and a 52-week high of $90.32. The business's 50-day moving average price is $39.58 and its 200 day moving average price is $49.85. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.64 by $0.16. The company had revenue of $91.73 million for the quarter, compared to analysts' expectations of $88.55 million. On average, equities research analysts expect that Soleno Therapeutics will post -3.72 earnings per share for the current year.

Hedge Funds Weigh In On Soleno Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SLNO. Raymond James Financial Inc. acquired a new stake in shares of Soleno Therapeutics in the second quarter valued at approximately $25,000. Danske Bank A S purchased a new stake in Soleno Therapeutics in the 3rd quarter valued at approximately $27,000. Global Retirement Partners LLC lifted its stake in Soleno Therapeutics by 519.0% in the 4th quarter. Global Retirement Partners LLC now owns 619 shares of the company's stock valued at $29,000 after buying an additional 519 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in Soleno Therapeutics during the 3rd quarter valued at $37,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Soleno Therapeutics during the 4th quarter valued at $38,000. Institutional investors and hedge funds own 97.42% of the company's stock.

Key Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Neutral Sentiment: Multiple law firms and claim services are issuing investor alerts reminding shareholders of the May 5, 2026 lead‑plaintiff deadline and encouraging affected investors to come forward. These notices increase visibility of the litigation but are procedural in nature. SLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
• Negative Sentiment: Several firms (Hagens Berman, Kessler Topaz, Pomerantz, Rosen, etc.) have confirmed or publicized securities‑fraud class actions alleging material misstatements/omissions about Soleno’s Phase 3 program and the November 2025 disclosures about DCCR/VYKAT XR launch disruptions. This raises the risk of costly litigation, management distraction, and potential settlements. Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman
• Negative Sentiment: An analyst update from Oppenheimer (reported in media coverage) lowered expectations for the VYKAT XR launch and 2026 sales, trimming the growth/valuation story for Soleno and increasing downside risk if launch execution and uptake remain weak. A Look At Soleno Therapeutics (SLNO) Valuation As Oppenheimer Updates Vykat XR Launch And 2026 Sales Outlook

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company's scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company's lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.